Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
Status:
Recruiting
Trial end date:
2021-09-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Bevacizumab (Avastin) in combination with
Dexamethasone (Ozurdex) will be effective in reducing if not eliminating the macular edema
associated with the disease, central retinal vein occlusion (CRVO) in comparison to
Bevacizumab (Avastin) alone.